show
immunogen
modifi
vaccinia
ankara
mva
vaccin
strain
improv
delet
gene
without
diminish
abil
viru
replic
delet
gene
result
increas
virusspecif
immunoglobulin
product
class
switch
igg
isotyp
virusspecif
secret
splenocyt
delet
viru
provid
excel
protect
efficaci
virul
viru
challeng
result
suggest
delet
mutant
strain
superior
vaccin
perform
poxviru
vaccin
well
platform
vaccin
infecti
diseas
cancer
vaccinia
viru
vacv
use
live
viru
vaccin
smallpox
erad
campaign
use
ultim
led
erad
fatal
diseas
despit
phenomen
success
vaccin
gener
public
discontinu
due
high
rate
advers
event
includ
dissemin
vaccinia
progress
vaccinia
eczema
vaccinatum
enceph
estim
current
popul
vaccin
due
immunosuppress
inflammatori
skin
condit
heart
abnorm
everi
peopl
vaccin
seriou
advers
reaction
result
hospit
sinc
discontinu
widespread
poxviru
vaccin
increas
incid
human
poxviru
infect
throughout
world
includ
buffalopox
india
cantagalo
vaccinia
viru
south
america
cowpox
europ
danger
emerg
poxviru
monkeypox
zoonot
poxviru
caus
smallpoxlik
ill
fatal
rate
human
grow
concern
monkeypox
incid
increas
fold
sinc
monkeypox
endem
africa
outbreak
unit
state
associ
import
african
rodent
outbreak
result
case
attenu
strain
death
occur
addit
threat
emerg
poxviru
infect
also
concern
smallpox
viru
could
use
biowarfar
agent
result
widespread
sick
mortal
larg
unvaccin
popul
thu
safer
poxviru
vaccin
need
face
emerg
diseas
bioterror
safer
altern
tradit
poxviru
vaccin
use
attenu
replicationdefici
strain
modifi
vaccinia
ankara
mva
attenu
viru
occur
serial
passag
chicken
embryo
fibroblast
cef
result
delet
approxim
kb
vacv
genom
includ
gene
encod
immunomodulatori
protein
inabl
replic
mammalian
cell
mva
test
vaccin
protect
poxvirus
also
use
platform
vaccin
infecti
diseas
cancer
poxvirus
make
good
platform
vaccin
stabl
easi
produc
induc
robust
durabl
cellular
humor
immun
respons
accommod
insert
larg
piec
foreign
dna
mva
shown
safe
administ
immunodefici
mice
nonhuman
primat
human
recent
vaccin
trial
shown
mva
given
safe
infect
hiv
atop
dermat
two
popul
receiv
tradit
vaccin
thu
attenu
vacv
show
promis
safer
altern
poxviru
vaccin
also
platform
vaccin
mva
clearli
safer
concern
immunogen
efficaci
studi
compar
immunogen
mva
tradit
poxviru
vaccin
mva
unabl
elicit
level
antibodi
cell
tradit
poxviru
vaccin
strain
even
time
viru
administ
immunogen
mva
may
especi
concern
popul
alreadi
weaken
immun
system
cancer
patient
data
avail
suggest
multipl
dose
mva
may
need
administ
order
achiev
level
immunogen
obtain
tradit
replicationcompet
strain
one
strategi
use
enhanc
immunogen
mva
identifi
exclud
gene
immunosuppress
copenhagen
gene
western
reserv
strain
gene
mva
gene
one
gene
previous
shown
poxviru
gene
highli
conserv
sequenc
mammaliantrop
poxvirus
includ
mva
import
virul
factor
mous
model
increas
virul
western
reserv
wr
viru
nearli
requir
replic
viru
addit
shown
wr
suppress
vitro
mhc
class
iirestrict
antigen
present
follow
intranas
infect
mice
protein
mediat
immunosuppress
significantli
decreas
virusspecif
antibodi
product
cell
ctl
kill
result
inabl
control
viral
replic
target
organ
thu
contribut
morbid
mortal
host
unknown
whether
would
similar
effect
mva
gene
miss
mva
would
requir
function
mva
character
gene
function
background
mva
genom
describ
immunosuppress
effect
vacv
western
reserv
wr
stock
propag
use
cell
mem
contain
fetal
bovin
serum
fb
previous
describ
mva
stock
propag
use
virus
purifi
use
sucros
gradient
previous
describ
roper
cell
atcc
chick
embryo
fibroblast
cef
grown
dmem
contain
fb
immunostain
perform
previous
describ
cell
infect
titrat
either
mva
viru
h
cell
incub
dilut
polyclon
vacv
rabbit
antiserum
bei
resourc
h
follow
incub
dilut
goat
antirabbit
igg
hrp
h
ml
follow
substrat
solut
ad
well
visual
virusinfect
cell
ul
h
ul
dianisidinesatur
ethanol
ml
pb
dna
segment
contain
flank
region
e
coli
xanthin
guanin
phosphoribosyl
transferas
gpt
gene
amplifi
exist
mutant
made
wr
use
primer
pair
tcgtgttcatgatcttgttc
ttgcctagaccggatacta
pcr
product
transfect
n
propyl
n
n
ntrimethylammonium
methylsulf
dotap
roch
cell
infect
mva
strain
virus
select
media
contain
mycophenol
acid
sigma
recombin
virus
two
independ
mutant
line
design
plaqu
purifi
three
time
use
immunostain
protocol
describ
crude
stock
propag
cell
contain
fb
use
previous
describ
method
crude
viru
lysat
prep
pcr
incub
equal
volum
pcr
buffer
igep
mm
trishcl
ph
mm
mgcl
mm
kcl
mgml
proteinas
k
follow
heatinactiv
proteinas
k
recombin
virus
pcr
screen
absenc
gene
use
primer
describ
immunolog
experi
perform
use
independ
deriv
mutant
viru
isol
confirm
differ
seen
compar
mva
due
delet
gene
western
blot
perform
previous
describ
use
polyclon
rabbit
sera
primari
fibroblast
isol
old
chick
embryo
embryo
minc
cc
syring
trypsin
two
time
minut
cell
wash
treat
ammonium
chlorid
minut
ice
wash
count
prepar
use
onestep
growth
curv
onestep
growth
curv
perform
measur
viral
replic
cef
previous
describ
viru
foci
enumer
cell
use
immunostain
protocol
describ
femal
balbc
mice
infect
intramuscularli
im
fu
sucrosegradi
purifi
mva
viru
ul
mock
infect
pb
titer
confirm
day
infect
viru
dilut
use
infect
anim
challeng
experi
mice
vaccin
im
describ
infect
intranas
week
later
ld
virul
wr
mice
weigh
monitor
daili
sign
ill
human
euthan
use
isofluran
overdos
weight
loss
occur
experi
assess
immun
respons
five
mice
viru
group
sacrif
spleen
collect
ice
cold
rpmi
splenocyt
obtain
use
previous
describ
method
blood
sampl
collect
microcentrifug
tube
use
cardiac
stick
follow
centrifug
g
min
separ
antibodycontain
sera
red
blood
cell
sera
store
use
experiment
protocol
approv
anim
care
use
committe
east
carolina
univers
antibodi
respons
measur
similar
previou
work
nineti
sixwel
elisa
plate
immulon
thermo
electron
coat
overnight
ulwel
ul
crude
wr
viru
elisa
coat
buffer
trishcl
ph
plate
block
fbspb
room
temperatur
min
plate
wash
elisa
wash
buffer
pb
tween
nan
titrat
mous
sera
rang
dilut
mva
mice
pb
treat
mice
control
ad
plate
incub
room
temperatur
h
wash
alkalin
phosphatas
ap
conjug
goat
antimous
ig
igm
igg
igg
igg
southern
biotech
ad
incub
room
temperatur
h
plate
wash
time
develop
biorad
alkalin
phosphat
substrat
kit
absorb
read
nm
number
secret
spleen
cell
enumer
similar
previou
work
nineti
sixwel
plate
immulon
thermo
electron
coat
overnight
ul
antimous
mgml
pharmingen
plate
wash
block
buffer
ad
titrat
murin
splenocyt
rpmi
stimul
splenocyt
achiev
either
addit
wr
viru
multipl
infect
moi
use
wrinfect
stimul
cell
follow
incub
h
plate
wash
incub
ul
biotinyl
rat
antimous
pharmingen
mgml
h
plate
wash
incub
streptavidinap
h
plate
develop
agarosebcip
amp
mixtur
spot
count
use
dissect
microscop
color
intens
read
absorb
nm
cell
type
present
spleen
analyz
flow
cytometri
splenocyt
mva
mice
fix
paraformaldehyd
ice
min
wash
incub
min
antifc
block
bd
pharmingen
block
nonspecif
bind
antibodi
fc
receptor
follow
antimous
allophycocyanin
apc
pacif
blue
pacbl
phycoerythrin
pe
phycoerythrincyanin
conjug
monoclon
antibodi
ad
sampl
min
ice
clone
southern
biotech
clone
ebiosci
clone
ebiosci
clone
ebiosci
nk
marker
bd
pharmingen
granulocyt
marker
clone
bd
pharmingen
macrophag
marker
caltag
lab
mhc
ii
iaie
clone
ebiosci
sampl
run
lsr
ii
flow
cytomet
data
analyz
use
fac
diva
softwar
experi
repeat
least
time
repres
data
shown
twotail
student
test
use
compar
group
p
valu
consid
signific
statist
analys
perform
use
excel
microsoft
offic
previous
show
requir
replic
wild
type
vacv
wr
strain
inhibit
vitro
mhc
iirestrict
antigen
present
suppress
b
lymphocyt
respons
mice
infect
next
wish
determin
remov
attenu
vaccin
strain
would
affect
replic
increas
immunogen
determin
role
infect
attenu
poxviru
strain
mva
mutant
viru
miss
gene
construct
similar
previou
delet
mutant
wr
strain
design
pcr
product
contain
e
coli
gpt
gene
flank
region
either
side
transfect
mvainfect
cell
recombin
virus
select
purifi
confirm
success
knock
mva
pcr
analysi
perform
use
primer
flank
region
shown
fig
pcr
amplif
parent
mva
viru
yield
product
kbp
pcr
analysi
two
independ
isol
mutant
result
approxim
bp
larger
product
compar
product
parent
mva
expect
size
increas
result
insert
gptcontain
pcr
fragment
wild
type
detect
mutant
suggest
gene
success
remov
indic
mutant
purifi
mva
parent
viru
confirm
absenc
recombin
virus
western
blot
perform
analyz
reactiv
rabbit
polyclon
sera
use
lysat
mva
infect
cell
fig
protein
band
kda
approxim
size
recogn
lysat
wr
mvainfect
cell
protein
band
absent
infect
cell
togeth
data
indic
success
knock
mva
two
independ
deriv
mutant
previous
report
mutant
viru
made
wr
form
normal
size
plaqu
african
green
monkey
kidney
cell
replic
normal
sever
cell
line
mous
tissu
possibl
loss
wr
compens
anoth
vacv
protein
sinc
mva
miss
kb
genom
wr
assess
whether
might
requir
mva
replic
viru
form
normal
mvasiz
foci
cell
fig
indic
loss
appar
effect
normal
viral
replic
spread
cell
compar
kinet
replic
viru
parent
mva
viru
perform
onestep
growth
curv
fig
cell
infect
either
mva
h
inocula
remov
variou
time
post
infect
cell
media
collect
amount
viru
determin
titrat
cell
viru
produc
cell
differ
amount
viru
produc
mva
time
point
test
similarli
viru
supernat
show
decreas
viru
product
one
step
growth
curv
also
use
compar
growth
mva
primari
cef
time
point
test
requir
viral
replic
fig
similar
result
seen
use
virus
togeth
data
indic
requir
normal
replic
mva
cell
primari
cef
conclus
requir
vacv
replic
spread
cell
cell
loss
virul
wr
result
decreas
virul
mous
model
determin
whether
delet
effect
virul
mva
mice
infect
intramuscularli
im
pfu
purifi
mva
one
two
mutant
virus
typic
rout
administr
mva
dose
shown
elicit
measur
immun
respons
mockinfect
pb
control
mice
weigh
monitor
daili
lesion
sign
ill
shown
fig
mice
infect
either
mva
gain
weight
similar
pb
control
sign
ill
similar
result
seen
infect
matter
viru
use
contrast
intranas
vaccin
mice
pfu
virul
wr
result
signific
weight
loss
death
data
confirm
mva
virul
virul
alter
loss
gene
genom
effect
poxviru
vaccin
elicit
humor
cellular
immun
respons
arm
immun
system
shown
mediat
aspect
protect
poxviru
infect
previou
data
wr
indic
remov
gene
result
increas
cellular
humor
immun
hypothes
remov
mva
would
boost
immunogen
wr
possibl
protein
interact
anoth
viral
protein
requir
function
sinc
mva
sever
larg
delet
interact
protein
may
delet
render
nonfunct
begin
understand
effect
mva
immun
respons
compar
product
antivacv
specif
ig
sera
mice
infect
either
mva
one
two
virus
fig
infect
mice
significantli
greater
amount
antivacv
antibodi
pb
treat
control
mice
indic
respons
seen
vacvspecif
mice
infect
significantli
greater
amount
total
vacvspecif
serum
ig
infect
mva
day
post
infect
pi
indic
immunosuppress
mva
also
analyz
product
igg
subclass
day
pi
fig
antibodi
isotyp
switch
import
antibodi
function
day
mice
infect
viru
produc
significantli
vacvspecif
igg
igg
igg
infect
mva
signific
differ
igm
product
day
infect
either
mutant
viru
yield
similar
result
repres
data
shown
data
indic
mva
decreas
vacvspecif
antibodi
product
inhibit
isotyp
switch
igg
subclass
order
measur
effect
mva
cellular
immun
respons
infect
use
elispot
assay
measur
product
result
stimul
vacv
antigen
present
mhc
mice
infect
day
six
pi
splenocyt
harvest
assay
vacv
specif
product
significantli
vacvspecif
product
cell
mice
infect
compar
mice
infect
parent
mva
fig
day
pi
threefold
increas
number
spleen
cell
group
compar
mva
group
differ
reach
statist
signific
similar
result
seen
virus
splenocyt
stimul
vacvinfect
cell
produc
splenocyt
pb
control
mice
group
without
addit
viru
infect
cell
thu
demonstr
specif
respons
sinc
cell
produc
follow
vacv
infect
also
measur
percentag
cell
splenocyt
infect
mice
day
pi
fig
found
mva
infect
significantli
increas
percentag
cell
spleen
differ
mva
group
previous
note
vacv
wr
infect
induc
splenomegali
presum
system
specif
immun
respons
develop
spleen
size
increas
mice
infect
viru
miss
immunosuppress
gene
understand
mechan
immunosuppress
infect
mva
perform
flow
cytometri
measur
percentag
cellular
subset
within
spleen
mva
mice
day
pi
littl
chang
splenocyt
popul
fig
small
signific
increas
percentag
cell
express
marker
granulocyt
splenocyt
mice
compar
mvainfect
mice
fig
differ
maintain
day
pi
data
shown
also
day
pi
small
signific
increas
percent
natur
killer
nk
cell
found
group
compar
mva
group
data
shown
sinc
vitro
data
indic
wr
specif
affect
apc
also
look
apc
subset
within
spleen
includ
b
cell
macrophag
dendrit
cell
found
day
pi
small
signific
increas
percent
macrophag
spleen
mice
compar
infect
mva
fig
signific
differ
group
percentag
total
mhc
class
ii
express
cell
fig
thu
infect
mva
result
small
signific
increas
cell
express
fig
modestli
reduc
infectioninduc
increas
percentag
granulocyt
express
cell
spleen
fig
next
determin
whether
viru
would
efficaci
vaccin
protect
mice
lethal
vacv
challeng
remov
wr
strain
vacv
reduc
vaccin
efficaci
mani
studi
perform
determin
protect
antigen
epitop
vacv
recent
studi
shown
epitop
deriv
bind
certain
mhc
class
allel
therefor
test
whether
remov
mva
would
decreas
vaccin
efficaci
due
loss
predict
protect
epitop
perhap
increas
efficaci
due
enhanc
immun
respons
mice
vaccin
im
mva
pb
control
four
week
later
challeng
ld
virul
wr
viru
fig
pb
control
mice
quickli
lost
weight
die
day
post
challeng
mva
vaccin
mice
surviv
challeng
signific
weight
loss
sign
ill
similar
data
obtain
viru
isol
togeth
data
support
hypothesi
mvabas
vaccin
exclud
gene
immunogen
least
efficaci
wildtyp
mva
vaccin
previous
shown
mous
model
vacv
protein
wr
viru
virul
factor
increas
virul
nearli
fold
decreas
immunogen
sinc
highli
conserv
mammaliantrop
poxvirus
probabl
effect
mani
host
mammal
manuscript
provid
character
attenu
vacv
vaccin
strain
mva
show
inhibit
adapt
immun
includ
gener
secret
cell
antibodi
product
result
consist
observ
gene
wr
viru
requir
replic
mva
either
cell
cef
cell
mva
deriv
fortuit
vaccin
product
mutant
virus
passag
cef
mva
lost
mani
immunosuppress
gene
found
vacv
includ
secret
receptor
homolog
tnf
mva
retain
immunoevas
gene
includ
receptor
homolog
sinc
gene
lost
random
mutat
absenc
select
retent
certain
gene
probabl
simpli
random
sinc
mva
avirul
test
altern
safer
poxviru
vaccin
also
use
platform
vaccin
deliv
variou
antigen
includ
cancer
hiv
unfortun
mva
fail
elicit
high
level
b
cell
respons
tradit
replic
poxviru
vaccin
therefor
remov
mva
hope
increas
immunogen
result
experi
could
predict
howev
mva
might
lost
requir
viral
gene
passag
larg
genom
delet
show
inde
function
suppress
specif
immun
respons
background
mva
genom
remov
result
increas
antibodi
product
isotyp
switch
igg
subclass
secret
cell
suggest
remov
poxvirusbas
vaccin
enhanc
immunogen
wr
improv
immun
respons
absenc
correl
improv
control
viru
replic
target
organ
sinc
mva
replic
mammalian
tissu
could
perform
experi
possibl
remov
gene
would
diminish
poxviru
vaccin
efficaci
immun
respons
protect
howev
show
vaccin
viru
protect
mice
well
wild
type
mva
virul
challeng
remov
significantli
increas
virusspecif
ig
igg
igg
igg
latter
two
igg
subclass
specif
chosen
sinc
use
measur
immun
respons
respect
predominantli
respons
associ
smaller
lesion
size
decreas
viral
replic
mice
human
follow
vacv
infect
person
atop
dermat
produc
higher
level
cytokin
antibodi
associ
less
protect
respons
result
uncontrol
replic
viru
skin
addit
recombin
vacv
express
cytokin
virul
wildtyp
viru
howev
found
evid
skew
immun
respons
toward
less
protect
respons
instead
inhibit
class
switch
igg
igg
isotyp
data
consist
vitro
data
indic
specif
inhibit
mhc
class
ii
cell
interact
requir
induct
isotyp
switch
report
splenic
dc
vacvinfect
mice
defici
present
model
antigen
specif
cell
data
show
remov
gene
wr
caus
elev
antibodi
level
least
one
month
vaccin
suggest
delet
mutant
virus
may
give
effect
protect
longer
time
period
togeth
data
support
remov
gene
poxviru
vaccin
strain
use
poxviru
vaccin
infecti
diseas
cancer
lineberg
comprehens
cancer
center
univers
north
carolina
content
articl
sole
respons
author
necessarili
repres
offici
view
ncbc
nih
lineberg
cancer
center
would
also
like
thank
alic
tripp
gwen
jone
technic
assist
